Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy

Journal of Burn Care and Research

Volumn 33, Issue 6, 2012, Pages

  Akers, Kevin S ^a,b   Cota, Jason M ^c   Chung, Kevin K ^b,d   Renz, Evan M ^b,d   Mende, Katrin ^a,b   Murray, Clinton K ^a,b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF THE INCARNATE WORD   (United States)

^d US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ARTICLE; BURN; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; HUMAN; INTERMITTENT INFUSION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; SEPSIS; STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-BACTERIAL AGENTS; BURNS; CHI-SQUARE DISTRIBUTION; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROPENSITY SCORE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SEPSIS; STATISTICS, NONPARAMETRIC; VANCOMYCIN;

EID: 84870309175     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31825042fa     Document Type: Article

References (22)

1. ABA. American Burn Association National Burn Repository 2007 Report, Dataset Version 4.0. 2008.
2. Keen EF 3rd, Robinson BJ, Hospenthal DR, et al. Incidence and bacteriology of burn infections at a military burn center. Burns 2010;36:461-8.
3. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988;44:9-13.
4. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34:792-5. (Pubitemid 20142400)
5. Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47:635-54.
6. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
7. ATS/IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
8. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45: 2460-7. (Pubitemid 32801896)
9. Murray CK, Holmes RL, Ellis MW, et al. Twenty-five year epidemiology of invasive methicillin-resistant Staphylococcus aureus (MRSA) isolates recovered at a burn center. Burns 2009;35:1112-7.
10. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-70. (Pubitemid 46179340)
11. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-65. (Pubitemid 351650522)
12. Priziola JL, Smythe MA, Dager WE. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med 2010;38(6 Suppl):S145-54.
13. Chung KK, Juncos LA, Wolf SE, et al. Continuous renal replacement therapy improves survival in severely burned military casualties with acute kidney injury. J Trauma 2008;64 (2 Suppl):S179-85; discussion S185-7.
14. Painter J. Propensity score matching via SPSS. 2004, accessed 21 Nov. 2011; available from: http://www.unc.edu/~painter.
15. Liu C, Bayer A, Cosgrove SE, et al. Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55.
16. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62:168-71. (Pubitemid 351865892)
17. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42. (Pubitemid 39447034)
18. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6. (Pubitemid 351521995)
19. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14.
20. Jeurissen A, Sluyts I, Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011;37:75-7.
21. Palevsky PM, Zhang JH, O'Connor TZ, et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7-20. (Pubitemid 351931092)
22. Moriyama B, Henning SA, Neuhauser MM, Danner RL, Walsh TJ. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother 2009;43:1324-37.